| Date Filed | Type | Description |
| 08/18/2023 |
4
| Derakhshan Behrad (Chief Business Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 220,000 options to buy
@ $7.08, valued at
$1.6M
|
|
| 08/18/2023 |
4
| MOORE JOHN R (General Counsel) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 200,000 options to buy
@ $7.08, valued at
$1.4M
|
|
| 08/18/2023 |
4
| Carruthers R Michael (CFO) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 200,000 options to buy
@ $7.08, valued at
$1.4M
|
|
| 08/18/2023 |
4
| Russell Alan J (Chief Scientific Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 200,000 options to buy
@ $7.08, valued at
$1.4M
|
|
| 08/18/2023 |
4
| Semigran Marc (Chief Development Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 133,333 options to buy
@ $7.08, valued at
$944k
|
|
| 08/18/2023 |
4
| Donovan Joanne M. (CMO) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 200,000 options to buy
@ $7.08, valued at
$1.4M
|
|
| 08/18/2023 |
4
| KOCH KEVIN (President and CEO) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 600,000 options to buy
@ $7.08, valued at
$4.2M
|
|
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/14/2023 |
8-K
| Quarterly results |
| 06/28/2023 |
SC 13D/A
| Novo Holdings A/S reports a 9.6% stake in Edgewise Therapeutics, Inc. |
| 06/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits... |
| 06/16/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/11/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/03/2023 |
4
| Derakhshan Behrad (Chief Business Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Sold 1,747 shares
@ $8.9049, valued at
$15.6k
Exercised 5,208 restricted stock units
@ $0 |
|
| 05/03/2023 |
4
| MOORE JOHN R (General Counsel) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Sold 1,897 shares
@ $8.9049, valued at
$16.9k
Exercised 5,208 restricted stock units
@ $0 |
|
| 05/03/2023 |
4
| Carruthers R Michael (CFO) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Sold 1,336 shares
@ $8.9049, valued at
$11.9k
Exercised 5,208 restricted stock units
@ $0 |
|
| 05/03/2023 |
4
| Russell Alan J (Chief Scientific Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Sold 1,602 shares
@ $8.9049, valued at
$14.3k
Exercised 5,208 restricted stock units
@ $0 |
|
| 05/03/2023 |
4
| Donovan Joanne M. (CMO) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Sold 3,254 shares
@ $8.9049, valued at
$29k
Exercised 10,416 restricted stock units
@ $0 |
|
| 05/03/2023 |
4
| KOCH KEVIN (President and CEO) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Sold 3,203 shares
@ $8.9049, valued at
$28.5k
Exercised 10,416 restricted stock units
@ $0 |
|
| 03/07/2023 |
4
| Fox Jonathan C (Director) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 43,731 options to buy
@ $9.43, valued at
$412.4k
|
|
| 03/07/2023 |
3
| Fox Jonathan C (Director) has filed a Form 3 on Edgewise Therapeutics, Inc. |
| 03/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/23/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| Cormorant Global Healthcare Master Fund, LP reports a 4.7% stake in Edgewise Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 7% stake in Edgewise Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| Flynn James E reports a 6.2% stake in Edgewise Therapeutics, Inc. |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 13.6% stake in EDGEWISE THERAPEUTICS INC |
| 02/01/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/03/2023 |
4
| Semigran Marc (Chief Development Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 300,000 options to buy
@ $8.94, valued at
$2.7M
|
|
| 11/03/2022 |
8-K
| Quarterly results |
|